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WE have been interested in the selective action of alkylating agents and in
drug resistance in cancer chemotherapy (Wheeler, 1963). Our approach has been
to examine the alteration in some biochemical properties oftumour cells following
the administration of alkylating agents, in an attempt to correlate the biological
effects of the drugs with the metabolic changes which they produce. We have
chosen a series of clinically-important drugs-chlorambucil, busulphan and
melphalan-for detailed study, and the Yoshida ascites sarcoma (in drug-sensitive
and -resistant forms) as an experimental system (Ujhazy and Winkler, 1965).
An accompanying paper (Harrap and Hill, 1968) outlines our reasoning for
suspecting that factors additional to alkylation of DNA may have importance in
directing the therapeutic role of alkylating agents.
In the present paper we describe how the selected drugs affect the growth rate
of the neoplasm, and the size of the individual cells, and indicate an interesting
association between the biological effects of these drugs and their chemical
reactivities.
MATERIAL AND METHODS
Chemicals: Leukeran (chlorambudil) (ClCH2CH2)2.N.C6H4. (CH2)3COOH,
Myleran (busulphan) CH3SO2.O(CH2)40 .SO2CH3, and Alkeran (melphalan)
(CICH2CH2)2.N.C6H4.CH2.CHNH2.COOH were synthesised in the Chester
Beatty Research Institute. Reagent chemicals were obtained from Hopkin and
Williams Ltd. and British Drug Houses Ltd., AnalaR grades being used where
available.
Animals
Female Wistar rats ofthe CB strain were used at 6 weeks of age, having body
weights of approximately 200 g. The tumour was passaged by intraperitoneal
injection of 2 x 106 cells in saline containing 2000 units each of benzyl penicillin
and streptomycin. The resistant line was maintained by treatment, 3 days after
each routine passage, with 4 mg. melphalan per kg. body weight: this operation
was omitted in those animals which were to be used subsequently for experimental
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Drug dosage
Tumour inhibition studies, usingvarying doses ofdrugs, permittedthe selection
of two dose levels for subsequent experimentation: a " curative dose" which
resulted in complete regression of the sensitive tumour, and a " low " or "thera-
peutically ineffective dose " which was lethal to less than 5% ofthe sensitive cells.
Neither dose level affected the growth rate ofresistant cells. Drugs were admin-
istered as a single dose subcutaneously at varyingtimes aftertumourimplantation.
Table I lists the essential details.
Tumour grouth rate
The tumour growth rate was followed over a 10-day period. Animals were
killed daily by cervical dislocation, and the peritoneal contents aspirated with
successive 10 ml. quantities of 0 3% saline (0.05% w/v with respect to trisodium
EDTA*). The total volume of cell suspension was recorded, and the cell concen-
tration determined in an electronic particle counter, Model A (Coulter Electronics,
Kenmore, Chicago) with threshold and aperture current settings 15 and 2 respec-
tively.
Cytological studies
For macrophage counts, animals received 1 ml. colloidal carbon i.p. 1 hour
before death (Halpern et al., 1953): smears were prepared from the aspirated cell
suspension, and stained by the May Grunwald-Giemsa procedure. A measure
of cell viability was obtained by a dye-exclusion technique using Lissamine green.
The percentage composition of the aspirated cell suspension was then classified
under the headings: living tumour cells, dead tumour cells, macrophages, lympho-
cytes, neutrophils.
Cell volume
Cell volume was estimated by sedimentation in a haematocrit tube. A sus-
pension containing a known number of cells was introduced into a haematocrit
tube, and spun at 500g for 10 minutes at 40 C. The mean cell volume was calcu-
lated from the packed cell volume thus obtained. This method was designed to
provide a rapid (though arbitrary) measure for the comparison of cell sizes.
RESULTS
The growth curves of sensitive tumour cells in treated and control animals are
compared in Fig. 1. For each drug, a " curative dose " was administered sub-
cutaneously to the treated animals, while control animals received solvent only.
The total number of freely suspended cells in the peritoneal cavity of untreated
animals carrying the sensitive tumour reached a plateau value at a little over 109,
and these animals died 9 or 10 days after tumour implantation. The growth rate
ofuntreated resistant cells was similar to that ofsensitive cells, and was unaffected
by drug treatment.
Each of the three drugs, when given at " curative dose " levels, exerted
different effects on the proliferation ofsensitive tumour cells. The administration
* The following abbreviations will be used throughout this paper: EDTA-ethylenediamine
tetracetic acid; DNA-deoxyribonucleic acid; RNA-ribonucleic acid.
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FIG. 1.-Growth curves of sensitive cells in animals treated with " curative doses" of alky-
lating agent: 0 O O treated cells; 0--- ---- untreated cells. Drugs were
administered subcutaneously on day indicated by arrow. Each point represents the mean
from three animals.
TABLE I.-Drug Doses Administered
Dose (mg./kg. body weight)
Drug Solvent "Curative dose" "Low dose"
Chlorambucil Ethanolic/HCl-phosphate/ 8 1.5
propylene glycolt
Melphalan . Ethanolic/HCl-phosphate/ . 2 0-016
propylene glycolt
Myleran . Dimethyl sulphoxide . 20 4
t Dissolved drug in 1 volume 2% w/v HCI in ethanol and diluted with 9 volumes phosphate/
propylene glycol (prepared by dissolving 20 g. dipotassium hydrogen phosphate and 450 ml. propylene
glycol in water and diluting to 11.).
of Myleran resulted in an immediate reduction in cell number, while melphalan
treatment (2 mg./kg.) held up cell multiplication for 2 days. Chlorambucil had
no effect on the tumour growth rate during the 24 hours following treatment,
though the cell count commenced to decline after this period. By administering
melphalan at a lower dose (1 mg./kg.), it was possible to extend to 3 days the time
during which the peritoneal concentration of sensitive tumour cells remained
constant.
The composition of the peritoneal exudates obtained from Myleran and
chlorambucil-treated tumour-bearing animals is summarised in Table II (sensitive
cells) and Table III (resistant cells). The cellular composition of the aspirates
remained remarkably constant for both resistant and sensitive cells, though in the
latter case, by eight days there had been a considerable reduction in the number
of living tumour cells, and a corresponding increase in the proportion of macro-
phages, lymphocytes and neutrophils. Before day 8, treated cells were relatively
devoid ofvacuoles.
Large changes in mean cell volume occurred following the administration of
alkylating agents to animals carrying the sensitive tumour: the form ofthis varia-
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TABLE II.-Composition of Peritoneal Exudates from Animals Carrying Sensitive
Tumour Cells at Varying Times after Treatment (" Curative Dose ")
Percentage composition of peritoneal exudate
Time
A
after Chlorambucil Myleran
tumour ,A__ __ _ _A
implanta- Living Living
tion tumour Dead Macro- Neutro- Lympho- tumour Dead Macro- Neutro- Lympho-
(days) cells cells phages phils cytes cells cells phages phils cytes
5 . 81 0 5 8 6 . 81 1 10 0 8
6 91 6 0 1 2 . 88 1 5 2 4
7 90 5 1 2 2 85 1 7 0 7
8 63 1 11 16 9 . 85 1 7 0 7
TABLE III.-CoMposition ofPeritoneal Exudates from Animals Carrying Resistant
Tumour Cells at Varying Times after Treatment (" Curative Dose ")
Percentage composition of peritoneal exudate
Time A
after Chlorambucil Myleran
tumour ,A_ _,___A
implanta- Living Living
tion tumour Dead Macro- Neutro- Lympho- tumour Dead Macro- Neutro- Lympho-
(days) cells cells phages phils cytes cells cells phages phils cytes
5 . 90 0 0 4 6 . 89 1 4 1 5
6 . 91 6 0 1 2 . 85 7 6 1 1
7 94 2 1 1 2 93 1 5 0 1
8 . 95 1 0 0 4 . 94 1 3 0 2
tion in volume with time was dependent on the dose of drug administered. Two
discrete situations were encountered, according to whether the animals received a
" curative dose " or a " low dose " ofalkylating agent. The changes in mean cell
volume following a " curative dose " of drug are shown in Fig. 2: the increases in
mean volume of the sensitive cells (resulting in the volume doubling by 36 hours)
were similar from drug to drug: a small temporary increase also occurred in the
volume of resistant cells from animals treated with melphalan and Myleran.
However, in the case of "low dose" treatment (Fig. 3) the increase in volume was
temporary, and the cells ultimately recovered their untreated dimensions.
A maximum volume increase of 50% had occurred in the sensitive cells at 25
hours with Myleran, at 36 hours with melphalan, and at 49 hours with chloram-
bucil.
The biological reactivities ofthese drugs (in terms oftheir effects on the growth
rate and mean volume of the sensitive cells) are compared with their chemical
reactivities in Table IV.
DISCUSSION
The cellular composition ofaspirates from both resistant and sensitive tumour-
bearing animals indicated that over 80% of these cells were living tumour cells,
with the exception of aspirates from sensitive tumour-bearing animals 8 days
after " curative " treatment. In this case, the proportion of macrophages,
lymphocytes and neutrophils had increased, probably as a result of the extensive
autolysis of the tumour cells. With this exception, however, it seemed unlikely
that entities other than living tumour cells would contribute measurably to the
chemical determinations in subsequent work.
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CELL VOLUME CHANGES AFTER CURATIVE
DOSE TREATMENT
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FIG. 2.-Cell volume changes following " curative dose " treatment. Filled symbols-
sensitive cells, open symbols-resistant cells: * O O Melphalan
(4 mg./kg.); *- ----- -- , F-1---El--- El Myleran (20 mg./kg.); A-*..-A ,
A/-* A.- A chlorambucil (8mg./kg.). Drugs administered subcutaneously 5 days
after tumour transplantation. Each point represents the mean from three separate
animals-overall scatter at each point 20%.
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FIG. 3.-Cell volume changes following " low dose " treatment. Filled symbols-sensitive
cells, open symbols-resistant cells: * 0 0, 0 O O, melphalan
(O0016mg./kg.); *-------, 0 - []--- myleran (4mg./kg.); A
- - ,&
AL /\ - A- A chlorambucil (1.5 mg./kg.). Drugs administered subcutaneously 5 days
after tumour transplantation. Each point represents the mean from three separate
animals-overall scatter at each point :F 10%.K. R. HARRAP AND BRIDGET T. HILL
TABLE IV.-A Comparison of the Biological and Chemical Reactivities of
Chlorambucil, Myleran and Melphalan
Biological reactivity
, ~~ ~~~AA
Change in number
Time (hours) of sensitive
required to elicit tumour cells Chemical
maximal increase during 24 hours reactivity
in volume of following drug " i life of
sensitive cells administration hydrolysis " at
Drug (low dose) (" curative dose ") 370 C. (min.)*
Chlorambucil 49 +3-4 x 108 . 30*
Melphalan . 36 Nil . 80*
Myleran . 25 -1P5 x 108 . 480t
* (Ross, 1962).
t (Ross, 1968, personal communication).
The Yoshida ascites sarcoma is evidently a useful system for the investigation
of quantitative differences between alkylating drugs. At the " curative" level,
the rate of sensitive cell proliferation following drug administration varied
according to the particular drug used. The order of drug effectiveness on this
basis could be represented as: Myleran > melphalan > chlorambucil. Chloram-
bucil had no immediate effects on the growth rate of sensitive cells, while Myleran
induced cell death at a rate greater than that of cell proliferation. The plateau
encountered in the growth curve of sensitive cells following melphalan treatment
wouldhave occurred ifthe rates ofcell death and cellproliferation were equivalent,
or alternatively if neither cell death nor proliferation were taking place.
At the " low dose " level, the time taken for the cells to achieve their maximum
increase in volume varied according to the drug used, the order of biological
reactivity again being Myleran > melphalan > chlorambucil. It was interesting
that this order ofbiological effectiveness was the inverse ofthe chemical reactivity
of these compounds, as measured by their " half lives of hydrolysis ". It should
be noted, of course, that although the latter represents an effective means of
comparing the chemical reactivities of chlorambucil and melphalan (both SNI
reactors), it gives only a semi-quantitative comparison between these two drugs
and Myleran (an SN2 reactor) (cf. Ross, 1962).
" Curative " doses ofeach ofthe three drugs produced comparable and irrever-
sible changes inthevolume ofthe sensitive cells, whichgreatlyexceeded thevolume
changes induced at the " low dose " level. The increase in cell volume was not
attributable to increased vacuolisation.
The finding that the biological reactivity ofthese drugs was in inverse order of
their chemical reactivities may indicate one of several possibilities:
(i) The rate of drug uptake varied from drug to drug, less chemically-active
drugs being transported more effectively than the more active agents.
(ii) The alkylating ability of the more chemically active drugs was lost by
hydrolysis, or by spurious alkylations leading to a reduction in the drug
available for reactions at " target sites ".
(iii) The drugs may be sequestered in vivo with resultant modification of
chemical reactivity. Support for this speculation is derived from the
ability ofprotein to modify the chemical andbiological reactivities ofsome
alkylating agents (Wade et al., 1967).
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(iv) The therapeutic effectiveness of these drugs is likely to be mediated
through alkylation of DNA (Lawley and Brookes, 1965), and the rate of
this reaction must vary from drug to drug, presumably as a result of the
competing effects of possibilities (i)-(iii) above.
With regard to possibilities (i) and (ii), recent experiments have shown that
sensitive and resistant ascites cells in vitro take up comparable molar quantities
of a given alkylating agent (Harrap and Hill, unpublished data). Possibilities
(iii) and (iv) are at present under examination.
There have been several reports of the increase in volume of mammalian cells
(growing in vivo and in vitro) following the administration of cytotoxic chemicals
or the application of X-rays (Sato et al., 1956; Vesela et al., 1965; Cohen and
Studzinski, 1967). In the case of bifunctional alkylating agents this effect has
been attributed to the premitotic arrest of cell division resulting from cross-linking
of DNA strands (reviewed by Loveless, 1966). Frequently the increase in cell
size has accompanied an increase in protein and RNA content, little or no vacuola-
tion being detected (Klein and Forssberg, 1954; Levis and de Nadai, 1964; Green
and Bodansky, 1962), and in such circumstances it has been observed that DNA
synthesis was arrested by the agent in question, while RNA and protein synthesis
continued (Eidinoff and Rich, 1959). This behaviour has been described as
" unbalanced growth " by analogy with a similar situation in micro-organisms
(Cohen and Barner, 1954). In the present communication we have observed both
reversible and irreversible increases in cell volume, depending on the dose of
alkylating agent used: " curative doses " of the drugs have resulted in progressive
and irreversible increases in the volume of the sensitive cells, while " low dose "
administration produces a temporary and smaller rise in volume. Two interpreta-
tions of these findings are possible: (i) if it is assumed that all the effects conse-
quent upon the interaction ofthe drug with the cells are attributable to the ability
of the drug to alkylate DNA, then the irreversibility of the cell volume changes
observed at " curative doses " must be due to extensive alkylation and formation
of DNA cross-links. At the " low dose " level, the reversibility of the smaller
volume changes imply that the cell is able to overcome a less extensive alkylation
of DNA (i.e. this behaviour conforms with an " excision and repair " hypothesis
(Lawley and Brookes, 1965; Crathorn and Roberts, 1966). (ii) On the other hand,
if it is agreed that these drugs are able to elicit extensive metabolic alterations at
the cytoplasmic level, in addition to DNA alkylation, then the " curative dose "
effects may be attributable to a composite of these two effects, while at the lower
dose only cytoplasmic modifications and no DNA alkylation occur. Our present
data are insufficient to decide between these alternatives.
SUMMARY
The suitability of the Yoshida ascites sarcoma as an experimental model for
comparing the quantitative biological effects elicited by a series of alkylating
agents has been examined. Myleran, chlorambucil and melphalan all influence
the rate of proliferation and volume of the tumour cells, though the order of
biological activity in these respects is the inverse ofthe order ofchemical reactivity.
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